Systems Pharmacology-Dissection of the Molecular Mechanisms of Dragon’s Blood in Improving Ischemic Stroke Prognosis

Figure 6

The neuroprotective effects of loureirin B were regulated by AKT, CREB, and Nrf2. (a) PC12 cells were exposed to loureirin B for 0 to 4 h after 4 h OGD, and then cell extracts were prepared for western blotting. (b) PC12 cells were treated with 10 μM loureirin B for 1 to 8 h after 4 h OGD, then the nucleoprotein was extracted to test the Nrf2. (c) PC12 cells were treated with 10 μM loureirin B reperfusion culture for 1 to 18 h after 4 h OGD. Then, the total protein was extracted with western blotting (d) after 4 h OGD; PC12 cells were treated with the different doses of loureirin B for 1.5 h, and then cell extracts were equipped for western blotting. (e) The activation of the pathway by loureirin B was inhibited by LY294002: after 4 h OGD, PC12 cells were treated with loureirin B (10 μM) in the absence and presence of 20 μM LY294002 as indicated for 1.5 h. (f) Inhibition of PI3K in loureirin B-induced HO-1 expression and Nrf2 nuclear translocation. After 4 h OGD, cells were incubated with 10 μM loureirin B in the absence and presence of 20 μM LY294002 for 6 h. Data in Figure 6(b) are presented as the mean ± SD (n = 3). .

(a)

(b)

(c)

(d)

(e)

(f)